Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Raltitrexed (D1694)(IC50 of 9 nM), a thymidylate synthase inhibitor, is used for the inhibition of L1210 cell growth.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | In stock | $ 34.00 | |
10 mg | In stock | $ 47.00 | |
25 mg | In stock | $ 89.00 | |
50 mg | In stock | $ 158.00 | |
100 mg | In stock | $ 293.00 | |
200 mg | In stock | $ 495.00 | |
500 mg | In stock | $ 783.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 38.00 |
Description | Raltitrexed (D1694)(IC50 of 9 nM), a thymidylate synthase inhibitor, is used for the inhibition of L1210 cell growth. |
Targets&IC50 | TS:9 nM |
In vitro | Raltitrexed induces double-stranded DNA breaks in a concentration-dependent manner. In Lovo cells and LS174T cell lines containing wild-type p53, Raltitrexed increases the levels of the Bax protein up to 5-fold. In human colon cancer cells, Raltitrexed is actively absorbed into cells and is then rapidly and extensively metabolized into a series of polyglutamates, which results in the effective inhibition of thymidylate synthase. Raltitrexed is delivered to the brain very quickly and can be detected in all brain tissues within 5 minutes. In human colon cancer cells, the combination of Raltitrexed and SN-38 results in a synergistic cytotoxic effect within a range of concentrations. Raltitrexed is a specific folate-based inhibitor of thymidylate synthase. The effect on the activity of advanced rectal cancer is similar to fluorouracil (5-fluorouracil) plus leucovorin. Raltitrexed produces activity by rapid cell entry and glutamination. The glutaminated derivatives are more than 100 times more active than the parent compound. In the HCT-8 cell line, Raltitrexed results in an increase in intracellular phosphoribosyl pyrophosphate (PRPD) indicating that the cytotoxic effect of Raltitrexed in combination with 5-FU is due to increased nucleotide formation of 5-FU. Combinations of Raltitrexed and folinic acid (5FU-FA) show a combination of mode-dependent, synergistic inhibition of proliferation, which is determined by measuring the combination series. Raltitrexed combined with Vorinostat produced significant synergistic effects of cell cycle perturbation and S-phase arrest. |
In vivo | Raltitrexed can be transported directly into the brain through the olfactory pathway in rats. |
Synonyms | ZD1694, D1694, ICI-D1694, Tomudex |
Molecular Weight | 458.49 |
Formula | C21H22N4O6S |
CAS No. | 112887-68-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: < 1 mg/mL (insoluble or slightly soluble)
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 84 mg/mL (183.2 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Raltitrexed 112887-68-0 Cell Cycle/Checkpoint DNA Damage/DNA Repair Nucleoside Antimetabolite/Analog DNA/RNA Synthesis ZD1694 Thymidylate Synthase ICI-D-1694 D-1694 ZD-1694 D1694 inhibit D 1694 Inhibitor ICI-D1694 ICI-D 1694 ZD 1694 Tomudex inhibitor